SCHEMBL13650443

SCHEMBL13650443

Nc1nc2c(c(N3CCCCCNCCCC3)n1)CCCC2c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 14/20 0.80
HRH3 Q9Y5N1 6/20 0.80
NOS1 P29475 2/20 0.44
NPY5R Q15761 1/20 0.42
KCNH2 Q12809 2/20 0.38
ADRB1 P08588 1/20 0.37
TACR2 P21452 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
CCR1 P32246 1/20 0.37
HRH1 P35367 1/20 0.37
AVPR1A P37288 1/20 0.37
HTR2B P41595 1/20 0.37
HTR3A P46098 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
HRH2 P25021 1/20 0.37
CHRM3 P20309 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650442 0.99 HRH4 (0.78) HRH4HRH3NOS1NPY5RKCNH2
SCHEMBL13650440 0.99 HRH4 (0.82) HRH4HRH3NOS1NPY5RKCNH2
SCHEMBL13650438 0.98 HRH4 (0.80) HRH4HRH3NOS1NPY5RKCNH2
SCHEMBL603530 0.92 HRH4 (0.93) HRH4HRH3NOS1KCNH2ADRB1
SCHEMBL606676 0.89 HRH4 (1.00) HRH4HRH3NOS1KCNH2ADRB1
SCHEMBL13650561 0.88 HRH4 (0.78) HRH4HRH3NOS1KCNH2ADRB1
SCHEMBL13650328 0.87 HRH4 (0.77) HRH4HRH3NOS1NPY5RKCNH2
SCHEMBL13650441 0.87 HRH4 (0.69) HRH4HRH3NOS1NPY5RHRH1
SCHEMBL13650564 0.85 HRH4 (0.74) HRH4HRH3NOS1KCNH2ADRB1
SCHEMBL13650354 0.85 HRH4 (0.73) HRH4HRH3NOS1KCNH2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885NOS1 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.